Cargando…
SUN-LB030 Empagliflozin Causing Euglycemic Diabetic Ketoacidosis
Background: Empagliflozin is a sodium glucose co-transporter 2 (SGLT-2) inhibitor that works in the proximal renal tubules reducing resorption of glucose and increasing urinary glucose excretion. It effectively lowers glycated hemoglobin (HbA1C) values and reduces risks of adverse cardiovascular eve...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Endocrine Society
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552746/ http://dx.doi.org/10.1210/js.2019-SUN-LB030 |